 G100 contains a potent synthetic small molecule toll-like receptor-4 TLR-4 agonist, Glucopyranosyl Lipid A GLA that leverages the activation of both innate and adaptive immunity, including dendritic cells, in the tumor microenvironment to create an immune response against the tumors preexisting diverse set of antigens. 